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PGC-1 (peroxisome proliferator-activated receptor  coactivator
1) is a master regulator of mitochondrial biogenesis and plays an
important role in several other aspects of energy metabolism. To
identify upstream regulators of PGC-1 gene transcription, 10,000
human full-length cDNAs were screened for induction of the
PGC-1 promoter. A number of activators of PGC-1 transcription
were found; the most potent activator was the transducer of
regulated CREB (cAMP response element-binding protein) binding
protein (TORC) 1, a coactivator of CREB. The other two members of
the TORC family, TORC2 and TORC3, also strongly activated PGC-1
transcription. TORCs dramatically induced PGC-1 gene transcrip-
tion through CREB. Forced expression of TORCs in primary muscle
cells induced the endogenous mRNA of PGC-1 and its down-
stream target genes in the mitochondrial respiratory chain and TCA
cycle. Importantly, these changes in gene expression resulted in
increased mitochondrial oxidative capacity measured by cellular
respiration and fatty acid oxidation. Finally, we demonstrated that
the action of TORCs in promoting mitochondrial gene expression
and function requires PGC-1. Previous studies had indicated that
TORCs function as a calcium- and cAMP-sensitive coincidence
detector and mediate individual and synergistic effects of these
two pathways. Our results, together with previous findings,
strongly suggest that TORCs play a key role in linking these
external signals to the transcriptional program of adaptive mito-
chondrial biogenesis by activating PGC-1 gene transcription.
M itochondrial biogenesis is an adaptive biological processthat occurs in response to developmental and physiologic
cues. Over the past decade, significant insights have been gained
into themolecular regulatory cascades controlling mitochondrial
biogenesis and function (1). Peroxisome proliferator-activated
receptor  coactivator 1  (PGC-1) was originally identified as
a coactivator of peroxisome proliferator-activated receptor
(PPAR) and regulator of adaptive thermogenesis (2) and then
subsequently found to coactivate many more transcription fac-
tors and play a central integrative role in mitochondrial biogen-
esis (3). In vitro and in vivo studies have demonstrated that
PGC-1 also plays a multifaceted role in regulating energy
metabolism in various tissues (4). Furthermore, the expression of
PGC-1 and mitochondrial oxidative capacity were reduced in
muscle from diabetic individuals (5, 6) and with aging (7).
Whether the reduced expression of PGC-1 and mitochondrial
biogenesis play a causal role in the initiation or development of
diseases remains to be determined. Nevertheless, improvement
or restoration of mitochondrial function may provide a thera-
peutic approach for the treatment of these diseases.
To identify upstream regulators controlling PGC-1 transcrip-
tion, an unbiased functional genomic screen was performed by
using a PGC-1 promoter–luciferase reporter gene assay. A
number of activators were identified that induced PGC-1
promoter activity. Among the hits, including transcription fac-
torsregulators, kinases, and ion channels, TORC1 was the most
potent activator. The TORC family, including TORC1, TORC2,
and TORC3, were originally identified as coactivators of CREB,
which greatly enhance CREB-dependent gene transcription (8,
9). In this study, we investigated the effect of the TORC family
on PGC-1 transcription and mitochondrial biogenesis in pri-
marymousemuscle cells. Furthermore, we providedmechanistic
insights by which TORCs modulate mitochondrial biogenesis.
Results
TORCs Strongly Activate PGC-1 Gene Transcription. The Origene I
clone collection, which contains 10,000 putative human full-
length cDNA clones, was screened for the ability to induce the
activity of the mouse 2 kb PGC-1 promoter (10) in HeLa cells.
A TORC1 cDNA was identified as the most potent inducer of
PGC-1 reporter from this screen. In addition to TORC1,
several other genes were identified from the screen that strongly
induced PGC-1 transcription (Table 1, which is published as
supporting information on the PNAS web site). As shown in Fig.
1A, transfection of a TORC1 expression vector with the PGC-1
promoter luciferase construct (PGC1-Luc) markedly induced
the activity of PGC-1 promoter. To determine whether acti-
vation of PGC-1 transcription was CREB-dependent, a cDNA
encoding a dominant negative CREB, ACREB, was cotrans-
fected along with a TORC1 expression vector and PGC1-Luc.
The basal activity of the PGC-1 promoter was significantly
suppressed by ACREB (Fig. 1A, lane 3 vs. lane 1). The activation
of the PGC-1 promoter by TORC1 was markedly suppressed by
ACREB (Fig. 1A, lane 4 vs. lane 2), suggesting that TORC1
activates PGC-1 transcription through CREB on the CRE site
within the PGC-1 promoter.
To determine whether activation of PGC-1 promoter is
sufficient to induce expression of endogenous PGC-1, HeLa
cells were transduced with a lentivirus expressing either TORC1
or GFP. Total protein and RNA were extracted from the cells at
24 and 48 h after transduction. TORC1 protein was overex-
pressed in the cells transduced with the TORC1 lentivirus
compared with those transduced with GFP (Fig. 1B). As shown
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in Fig. 1C, the endogenous level of PGC-1 mRNA was signif-
icantly elevated by overexpression of TORC1 in HeLa cells
at both 24 and 48 h. We also examined the expression of
cytochrome c (Cyt c), a PGC-1 target gene. Cyt c mRNA level
increased by 2-fold in the cells transduced with TORC1 com-
pared with the GFP controls (Fig. 1D). These data indicate that
the activation of the PGC-1 promoter led to increased expres-
sion of PGC-1 and its target gene Cyt c, suggesting that
mitochondrial gene expression andor biogenesis might be in-
creased upon TORC overexpression.
The TORC family has two other members, TORC2 and
TORC3, which share 30–40% homology with the TORC1
protein. The distribution of the mRNAs from the three TORC
genes in human tissues is shown in Fig. 2A. TORC1 mRNA
expression was highest in brain and very low, by comparison, in
all other tissues examined. Conversely, TORC2 and TORC3 are
ubiquitously expressed in the tissues examined, and both are
expressed at a significant level in the skeletal muscle. To
determine whether TORC2 and TORC3 can also activate
PGC-1 transcription, plasmids expressing hTORC2 or
hTORC3 were cotransfected into the HeLa cells along with the
PGC-1 promoter. As shown in Fig. 2B, both TORC2 and
TORC3 strongly activated the PGC-1 promoter. In the pres-
ence of ACREB, the activation by TORC2 or TORC3 was
markedly suppressed.
TORCs Induce Mitochondrial Biogenesis in Muscle Cells. TORCs are
regulated by nuclear import, which is induced by both cAMP-
and calcium-signaling pathways (9, 11). Interestingly, both path-
ways are also activated during contraction and exercise as well as
cold adaptation, and these processes lead to the induction of
PGC-1 and mitochondrial biogenesis in skeletal muscle and
brown adipose tissue (10, 12–15). The requirement of PGC-1
activation by TORCs in these processes has not been deter-
mined. Thus, we investigated the effect of TORCs on PGC-1
expression and mitochondrial biogenesis in mouse primary
muscle cells. Mouse primary myotubes were transduced with an
adenovirus expressing hTORC1, hTORC2, hTORC3, or GFP
for 48 h. Total protein was extracted from the cells, and the
human TORC1, TORC2, and TORC3 protein levels were
determined by Western blot analysis. As shown in Fig. 3, the
expression levels of human TORC1 (Fig. 3A), TORC2 and
TORC3 (Fig. 3B) proteins were expressed in the cells transduced
with the appropriate TORC adenovirus. To determine whether
forced expression of TORCs induced endogenous PGC-1
expression, total RNA was extracted from these muscle cells and
subjected to quantitative (Q)-PCR analysis. Fig. 3C shows that
PGC-1mRNA levels were increased approximately 3-fold with
TORC1 or TORC2 and 8-fold with TORC3 compared with the
GFP control. To determine whether induction of PGC-1 can
activate the mitochondrial biogenic program in these cells, the
expression levels of PGC-1 target genes were examined. Es-
trogen related receptor  (ERR) an early target gene of
PGC-1 during mitochondrial biogenesis, was significantly ele-
vated by TORC2 and TORC3 (Fig. 3D). Genes that are involved
in the mitochondrial respiratory chain and TCA cycle, such as
Cyt c, Cox II (Cytochrome oxidase subunit II), and IDH3
(isocitrate dehydrogenase 3 ) were also significantly increased
(Fig. 3 E–G). Both Cyt c and IDH3 are nuclear genome-
encoded genes, whereas Cox II is a mitochondrial genome-
encoded gene. The induction of Cox II suggests that mitochon-
drial DNA replication is increased. These results suggest that
TORCs promote mitochondrial biogenesis by increasing the
expression of both nuclear- and mitochondrial-encoded genes.
TORCs Enhance Mitochondrial Oxidative Capacity in Muscle Cells.We
further investigated whether induction of mitochondrial gene
expression by TORCs has an impact on mitochondrial function,
especially oxidative phosphorylation. Cellular respiration was
measured from the mouse primary muscle cells transduced with
either TORC or GFP adenovirus for 48 h (Fig. 4A). Coinciding
with the induction of gene expression in the respiratory chain,
Fig. 1. TORC1 induces PGC-1 and Cyt c expression in HeLa cells. (A) HeLa cells were transfected with pGL3-basic-PGC1-Luc (40 ng) and phRL-SV40 (3 ng, as
control for transfection efficiency) along with the indicated cDNA constructs (TORC1, 60 ng; ACREB, 60 ng). The cells were lysed, and the luciferase activity was
determined 48 h after transfection. The luciferase activity represents the ratio of firefly luminescence over renilla luminescence, an index of PGC-1 gene
transcription; n  6. *, P  0.05 lane 2 vs. lane 1; **, P  0.05 lane 3 vs. lane 1; #, P  0.05 lane 4 vs. lane 2. (B–D) HeLa cells were transduced with a lentivirus
expressing either GFP or TORC1. Total protein was extracted from cells 48 h after transduction and subjected to Western blot analysis to determine the expression
of TORC1 protein (B). Total RNA was extracted from the cells at 24 and 48 h after transduction and subjected to Q-PCR analysis to determine the expression level
of endogenous PGC-1 (C) and Cyt c mRNA (D). The average relative expression (mean  SEM) is shown. *, P  0.05 TORC1 vs. GFP; n  3.
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the basal cellular respiration, without treatment, was elevated
22%, 37%, and 174% by overexpression of TORC1, TORC2, and
TORC3, respectively. Oligomycin-insensitive respiration, the
proton leak, was not affected by overexpression of TORCs.
Consistent with this observation, we found that the expression of
UCP2 and UCP3, two major UCPs expressed in these cells, was
not altered (data not shown). Carbonyl cyanide p-trif luorome-
thoxyphenylhydrazone (FCCP)-stimulated cellular respiration,
indicative of mitochondrial maximum capacity, was increased
20%, 49%, and 200% by TORC1, TORC2, and TORC3, respec-
tively (Fig. 4A). These results demonstrate that TORCs not only
induced mitochondrial gene expression, but also enhanced mi-
tochondrial oxidative capacity in the muscle cells.
Another important pathway in the mitochondria for energy
metabolism is fatty acid -oxidation. To determine whether
TORCs affect this pathway, myotubes were transduced with
TORC2, TORC3, or GFP adenovirus for 48 h. Cells were then
labeled with [14C]palmitate for 2 h, and the complete oxidation
product, 14CO2, was measured. As shown in Fig. 4B, the fatty acid
oxidation rate was increased 28% and 45% in the cells overex-
pressing TORC2 and TORC3, respectively, compared with the
GFP control. TORC1 overexpression, however, did not elevate
the fatty acid oxidation significantly in these cells.
Induction of Mitochondrial Biogenesis by TORCs Requires PGC-1.
CREB is known to regulate the transcription of a number of
mitochondrial proteins directly (16–20). A crucial question is
whether the induction of mitochondrial gene expression by
TORCs depends on PGC-1. To investigate this question, we
used primary muscle cells from WT and PGC-1 KO mice.
These cells were transduced with TORC2, TORC3, or GFP
adenovirus for 48 h. Total RNA was extracted, and the expres-
sion of PGC-1 and its target genes, ERR and Cyt c, was
measured by Q-PCR. As expected, PGC-1 expression was
significantly increased by overexpression of TORCs in the WT
myotubes but not in the PGC-1-null myotubes (Fig. 5A). ERR
mRNA levels were significantly elevated in the WT PGC-1
myotubes by TORCs, however, this increase was completely
abolished in the null myotubes (Fig. 5B). Cyt c expression was
elevated by TORCs in the WT myotubes, and this induction was
markedly, but not completely, abolished, in the PGC-1-null
myotubes (Fig. 5C). In contrast to the PGC-1 target genes, the
expression of desmin, a myogenic-specific marker, was not
altered (Fig. 5D). These results indicate that the effect of TORCs
on mitochondrial biogenesis largely depends on PGC-1.
Discussion
Based on an unbiased screen, we have identified TORCs as the
most potent activators for PGC-1 gene transcription. All three
members of the TORC family, TORC1, 2, and 3, markedly
increased PGC-1 promoter activity. This transcription activa-
tion by TORCs was strongly suppressed by ACREB, indicating
that TORCs increase PGC-1 transcription in a CREB-
dependent fashion. The TORC family had been identified as
coactivators of CREB and enhanced CREB-dependent gene
transcription (8). TORCs function as downstream effectors of
cAMP- and calcium-signaling pathways and appear to be an
essential component of inducible, CREB-mediated gene expres-
sion. TORC2 was shown recently to promote hepatic glucone-
ogenesis in response to fasting by inducing the expression of
PGC-1 (21). Interestingly, TORC2 also enhanced hepatic
insulin sensitivity by increasing IRS-2 expression, which sup-
presses hepatic gluconeogenesis (22). By playing a dual role in
controlling fasting hepatic gluconeogenesis, the CREB:TORC2
Fig. 2. TORC2 and TORC3 strongly induce PGC-1 transcription. (A) Human tissue distribution of the TORC family. The mRNA expression levels of TORC1, 2,
and 3 were measured by Q-PCR in a panel of human tissue cDNAs. The mRNA expression level of each TORC in brain is set at 100%. The mRNA expression levels
in other tissues is relative to that of brain. (B) TORC2 and TORC3 induce PGC-1 promoter activity. HeLa cells were transfected with pGL3-basic-2kb-PGC1-Luc
(40 ng) and phRL-SV40 (3 ng) along with various cDNA constructs, as indicated (TORC2 or TORC3, 10 ng; ACREB, 110 ng). The cells were lysed, and the luciferase
activity was determined at 48 h after transfection. The luciferase activity represents the ratio of firefly luminescence over renilla luminescence (mean  SEM).
*, P  0.05, lanes 2 and 3 vs. lane 1; #, P  0.05, lane 5 vs. lane 2 and lane 6 vs. lane 3; n  6








pathway thus triggers a feedback response that limits glucose
output from the liver during fasting. However, the role of the
TORC family in mitochondrial biogenesis and energy metabo-
lism in muscle was not known.
The calcium-signaling pathways play an important role in
triggering PGC-1 expression and mitochondrial biogenesis
upon exercise (12, 13, 23–28). We hypothesized that TORCs
might play a role in mediating PGC-1 expression and PGC-
1-dependent mitochondrial biogenesis in this process. Ectopic
expression of TORCs induced the expression of the endogenous
PGC-1mRNA as well as its downstream target genes including
ERR, a transcription regulator of mitochondrial biogenesis (29,
30) and mitochondrial markers including Cyt c, COX II, and
IDH3. Importantly, coinciding with the changes of gene ex-
pression, the oxidative capacity of these cells was enhanced,
indicated by increased cellular respiration as well as fatty acid
oxidation. These results clearly demonstrate that TORCs can
promote mitochondrial biogenesis and enhance oxidative capac-
ity in muscle cells.
We further dissected the mechanism by which TORCs pro-
mote mitochondrial biogenesis in muscle. We found that ectopic
expression of TORCs strongly induced the mRNA levels of
PGC-1, ERR, and Cyt c in the PGC-1 WT myotubes.
However, the induction of these genes by TORCs was drastically
suppressed in the PGC-1-null muscle cells. Conversely, the
expression of desmin, a myogenic marker and non-PGC-1
target, was not altered by overexpression of TORCs in either the
PGC-1 WT or the null muscle cells. These results clearly
demonstrate that the action of TORCs in promoting mitochon-
drial biogenesis requires PGC-1 and further highlights the
importance of PGC-1 in this process.
The three TORCs display differential tissue distribution pat-
terns (Fig. 2A) and subcellular localization (11). The activity of
TORC1 and TORC2 is regulated by calcineurin and salt-
Fig. 3. Adenoviral-mediated expression of TORCs increases mitochondrial gene expression. (A andB) Primary muscle cells were transduced with TORC1, TORC2,
TORC3, or GFP adenovirus. Total protein or RNA was extracted from the cells at 48 h after transduction, and 50 g of total protein extract from each sample was
subjected to Western blot analysis to determine the expression levels of TORC1 (A), and ectopically expressed TORC2 and TORC3 protein (B). The primary
antibodies used were anti-TORC1 inAand anti-V5 inB. The secondary antibody used was HRP-conjugated goat anti-rabbit IgG. Total RNA samples were subjected
to Q-PCR analysis. (C–G) The relative expression levels of the endogenous PGC-1 (C) and ERR (D), Cyt c (E), Cox II (F), and IDH3 (G) are shown. Mean  SEM;
n  3; *, P  0.05, TORC1, TORC2, or TORC3 vs. GFP.
Fig. 4. Adenoviral-mediated overexpression of TORCs increase mitochondrial oxidative capacity in muscle cells. Primary muscle cells were transduced with
TORC1, TORC2, TORC3, or GFP adenovirus for 48 h. (A) Cellular respiration was measured without treatment (basal) or with treatment, as indicated. The average
fold change over GFP (mean  SEM) is shown. (B) Cells were labeled with [14C]palmitate for 2 h, and the complete fatty acid oxidation rate indicated by the
amount of 14CO2 produced was determined. All experiments were performed in triplicate. *, P  0.05 for TORC vs. GFP; n  3.
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inducible kinases through dephosphorylation or phosphoryla-
tion, which promotes or blocks the translocation of TORC1 and
2, respectively, from the cytoplasm to the nucleus (9, 11).
TORC3, on the other hand, was shown to be localized in the
nucleus, mainly in the resting state in some cells, and had a higher
potency in enhancing CREB transcription activity compared
with TORC1 and 2 (11). Consistent with this finding, our results
show that TORC3 exerts a stronger effect in activating the
transcription of the PGC-1 gene as well as inducing mitochon-
drial biogenesis in muscle cells compared with TORC1 and
TORC2. Interestingly, the effect of TORC1 and TORC2 in
activating the PGC-1 promoter was diminished in the presence
of ACREB, indicating that this activation is entirely mediated
through CREB. The activation by TORC3, however, was sup-
pressed to a lesser degree (60%) compared with TORC1 and
TORC2 (90%). It is conceivable that the remaining activity by
TORC3 in the presence of ACREB is mediated through other
transcription factor(s). The identity of these other transcription
factors and their target sequences in the PGC-1 gene remains
to be determined.
In skeletal muscle, a large body of evidence indicates that, in
response to contractile activity, calcium-dependent signaling
pathways trigger regulatory events leading to increased oxidative
fiber content, mitochondrial biogenesis, and oxidative capacity
(31–33). The molecular mechanism by which activation of the
calcium signaling pathways, upon exercise in muscle cells, leads
to the induction of PGC-1-mediated mitochondrial biogenesis
has been elucidated by Handschin et al. (10). CREB and MEF2
are the two key transcription factors activated by calcineurin and
CaMKIV, which, in turn, activate PGC-1 transcription through
the CRE andMEF2 sites, respectively, on the PGC-1 promoter.
Akimoto et al. (13) showed that the activity of the PGC-1
promoter was activated in muscle in live mice upon electrical
stimulation and that the CRE and MEF2 sites on the PGC-1
promoter were critical for this activation. We demonstrate here
that TORCs strongly induced the PGC-1-dependent mitochon-
drial biogenesis and oxidative capacity in muscle. Our results,
together with the observation that TORC activation occurs
through calcium in a calcineurin-dependent fashion (11),
strongly suggest that TORCs play a key role in linking these
external signals, such as exercise, to the transcriptional program
of adaptive mitochondrial biogenesis by activating PGC-1
transcription.
Mitochondria are dynamic organelles and serve as the center
stage for oxidative metabolism, nucleotide and lipid biosynthe-
sis, apoptosis, and reactive oxygen species homeostasis. Dys-
regulation of mitochondrial function has been linked to various
human diseases, such as neurodegeneration, cancer, cardiomy-
opathy, and diabetes (34). Although it remains to be determined
whether mitochondrial dysfunction plays an etiologic role in the
development of any of these diseases, restorationimprovement
of mitochondrial function might delay the onset or have a better
control of these diseases. Therefore, enhancing mitochondrial
function through activation of PGC-1 by TORCs as well as
other identified gene hits from this study could potentially be a
therapeutic approach for the treatment of some these diseases.
Materials and Methods
cDNA Collection and Plasmids.TheOriGene I cDNA collection was
purchased from OriGene Technologies (Rockville, MD). The
collection contains 10,000 putative full-length human cDNA
clones representing 8,980 gene loci, covering 35% of Refseq-
annotated human genes. The mouse 2-kb PGC-1 promoter
Fig. 5. The effect of TORC2 and TORC3 on mitochondrial gene expression is primarily mediated through PGC-1. WT and PGC-1-null primary muscle cells were
transduced with TORC2, TORC3, or GFP adenovirus for 48 h. Total RNA was extracted, and the gene expression levels (mean  SEM) were measured by Q-PCR
analysis. *, P  0.05, TORC2 or TORC3 vs. GFP; n  3.








luciferase construct, pGL3-basic-PGC-1-Luc (PGC1-Luc),
and ACREB were described in ref. 10.
High-Throughput Transfection and Luciferase Reporter Gene Assay.
High-throughput DNA transfection in 384-well plates was per-
formed by using a Biomek FX liquid handling workstation
(Beckman-Coulter, Fullerton, CA) as described (35). The other
reporter gene assays were performed in 96-well plates.
Primary Mouse Myoblast Isolation and Differentiation. Primary mus-
cle cells were isolated from 2- to 3-week-old FVB mice as well
as the wild-type and PGC-1-null mice (36) as described (37). To
induce differentiation, myoblasts were grown to 80% confluence
and then switched to the differentiation medium, DMEM
(GIBCO, Carlsbad, CA) containing 5% horse serum (HyClone,
Logan, UT).
Lentiviral and Adenoviral Transduction.Generation of TORC1 and
GFP lentiviruses and transduction into HeLa cells were de-
scribed (see supporting information). The adenoviruses express-
ing human TORC1 or TORC2 and TORC3 were generated by
Welgen (Worcester, MA) and Invitrogen (Carlsbad, CA), re-
spectively. Primary muscle cells were transduced with the ade-
novirus of TORC2, TORC3, or GFP at 4  108 particles per ml
per well in 6-well plates. Medium was changed daily. Cells were
harvested 48 h after transduction for analysis.
RNA Extraction and Real-Time PCR Analysis of Gene Expression. Total
RNA was extracted from cells by using TRIzol (Invitrogen) and
subjected to TaqMan analysis. The relative mRNA expression
levels were calculated by comparing the target genes18S rRNA.
The TaqMan probe sequence of cytochrome oxidase subunit II
(Cox II) is 5-TCAAGCAACAGTAACATCAAACCGACCA-3.
The TaqMan primer sequences of Cox II are 5-CCATCCCAG-
GCCGACTAA-3 (forward) and CAGAGCATTGGCCATA-
GAATAACC (reverse). The TaqMan primerprobe sets for all of
the other genes examined were obtained from Applied Biosystems
(Foster City, CA).
Protein Extraction and Western Blotting. Cells were lysed by using
cell extraction buffer (Cat no. FNN0011; Biosource Interna-
tional, Camarillo, CA) supplemented with protease inhibitors.
Fifty micrograms of cell lysate was used for Western blot
analysis. The rabbit anti-human TORC1 polyclonal antibody (9)
was used at 1:2,000 dilution. Tubulin (Cat no. ab3194; Abcam,
Cambridge, MA) and V5 antibodies (Cat no. 960-25; Invitrogen)
were used at dilutions of 1:3,000 and 1:5,000, respectively. The
secondary antibodies, HRP-conjugated goat anti-rabbit IgG
(Cat no. 31460) and goat-anti-mouse IgG (Cat no. 31430) were
purchased from Pierce (Rockford, IL) and used at 1:10,000
dilution. The immunoblots were developed by using enhanced
chemiluminescence with Super Signal West Dura Chemilumi-
nescence kit (Cat no. 34075; Pierce).
Cellular Respiration and Fatty Acid Oxidation Measurements. Respi-
ration was measured in myotubes according to the published
method (38). Half a million mouse primary myotubes were used
for each measurement. The concentration of oligomycin (MP
Biomedicals, Solon, OH) and FCCP (Sigma, St. Louis, MO)
were 2 gml and 2–5 M, respectively. Fatty acid oxidation
assay was performed as described (39)
Statistical Analysis. Statistical analysis was performed on all of the
data by using a two-tailed, unpaired Student’s t test. A P value
0.05 was considered to be significant.
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